Trial Profile
Pilot Study of Carboplatin, Nab-Paclitaxel and Pembrolizumab for Metastatic Triple-Negative Breast Cancer
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 30 Oct 2023
Price :
$35
*
At a glance
- Drugs Carboplatin (Primary) ; Paclitaxel (Primary) ; Pembrolizumab (Primary)
- Indications Advanced breast cancer; Triple negative breast cancer
- Focus Therapeutic Use
- 26 Oct 2023 Results assessing safety and efficacy of Pembrolizumab and Chemotherapy in Metastatic Triple Negative Breast Cancer published in the Clinical Cancer Research
- 21 Nov 2022 Status changed from active, no longer recruiting to completed.
- 21 Sep 2020 Planned End Date changed from 1 Mar 2020 to 6 Feb 2022.